Bellerophon to Present at the JMP Securities Life Sciences Conference

WARREN, N.J., June 13, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. BLPH ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company, announced today that Fabian Tenenbaum, Chief Executive Officer, will present a corporate overview at the JMP Securities Life Sciences Conference, being held June 19-20, 2019, at the St. Regis New York Hotel in New York City.

Bellerophon Presentation Details

Date:   Thursday, June 20
Time:   11:00 AM Eastern Time
Location:   St. Regis New York Hotel, New York, NY
Webcast:   http://wsw.com/webcast/jmp39/blph/

About Bellerophon

Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The Company is currently developing multiple product candidates under its INOpulse program, a proprietary pulsatile nitric oxide delivery system.  For more information, please visit www.bellerophon.com.

Contacts    
At Bellerophon:   At LifeSci Advisors:
Fabian Tenenbaum, Chief Executive Officer    Brian Ritchie
(908) 574-4767   (212) 915-2578
    britchie@lifesciadvisors.com



Bellerophon logo.jpg

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsHealth CarePress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!